Investigators conducted a retrospective study of patients treated for early-stage breast cancer at Fred Hutch Cancer Center to identify clinicopathologic factors associated with SLN-positivity (SLN+), ...

Net sales totalled EUR 939.3 (January-June 2025: 771.0) million Operating profit was EUR 291.3 (182.5) million Basic earnings per share were EUR 1.64 (1.02) Cash flow from operating activities per ...

Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts ...